Star Combo Pharma Limited Fundamental Analysis
Star Combo Pharma Limited Fundamental Analysis
Star Combo Pharma Limited (S66.AX) shows moderate financial fundamentals with a PE ratio of 4.34, profit margin of 22.59%, and ROE of 14.06%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 71.1/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze S66.AX's fundamental strength across five key dimensions:
Efficiency Score
ExcellentS66.AX demonstrates superior asset utilization.
Valuation Score
ExcellentS66.AX trades at attractive valuation levels.
Growth Score
ModerateS66.AX shows steady but slowing expansion.
Financial Health Score
ExcellentS66.AX maintains a strong and stable balance sheet.
Profitability Score
ModerateS66.AX maintains healthy but balanced margins.
Key Financial Metrics
Is S66.AX Expensive or Cheap?
P/E Ratio
S66.AX trades at 4.34 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, S66.AX's PEG of 0.01 indicates potential undervaluation.
Price to Book
The market values Star Combo Pharma Limited at 0.47 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 2.09 times EBITDA. This is generally considered low.
How Well Does S66.AX Make Money?
Net Profit Margin
For every $100 in sales, Star Combo Pharma Limited keeps $22.59 as profit after all expenses.
Operating Margin
Core operations generate -1.71 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $14.06 in profit for every $100 of shareholder equity.
ROA
Star Combo Pharma Limited generates $11.46 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Star Combo Pharma Limited generates limited operating cash flow of $602.54K, signaling weaker underlying cash strength.
Free Cash Flow
Star Combo Pharma Limited generates weak or negative free cash flow of $253.90K, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
S66.AX converts 1.39% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
4.34
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.47
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.76
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.21
vs 25 benchmark
Current Ratio
Current assets to current liabilities
6.64
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.14
vs 25 benchmark
ROA
Return on assets percentage
0.11
vs 25 benchmark
ROCE
Return on capital employed
-0.01
vs 25 benchmark
How S66.AX Stacks Against Its Sector Peers
| Metric | S66.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 4.34 | 21.75 | Better (Cheaper) |
| ROE | 14.06% | 817.00% | Weak |
| Net Margin | 22.59% | -3758.00% (disorted) | Strong |
| Debt/Equity | 0.21 | 0.80 | Strong (Low Leverage) |
| Current Ratio | 6.64 | 2.33 | Strong Liquidity |
| ROA | 11.46% | 385.00% | Weak |
S66.AX outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Star Combo Pharma Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Dividend, Low Volatility
EPS CAGR
N/A
Industry Style: Defensive, Dividend, Low Volatility
FCF CAGR
N/A
Industry Style: Defensive, Dividend, Low Volatility